HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...

Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The ...

Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT’s Denifanstat, a first-in-class FASN ...

WEIFANG, SHANDONG, CHINA, January 21, 2026 /EINPresswire.com/ -- 1. Rising Global Demand for PDT LED Light Therapy As ...

From contrast therapy to rhythmic health, experts are placing renewed focus on recovery, rest, and repair. Read on for some ...

From contrast therapy to rhythmic health, experts are predicting a renewed focus on recovery, rest, and repair The wellness ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Rory Evans Rory Evans is a writer focused on skin-care and beauty products.

Acne vulgaris affects a large proportion of adolescents and young adults and can lead to long-term scarring and psychological distress. Its pathogenesis involves excessive sebum production, bacterial ...

Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.